<?xml version='1.0' encoding='utf-8'?>
<document id="21171670"><sentence text="Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects."><entity charOffset="80-92" id="DDI-PubMed.21171670.s1.e0" text="esomeprazole" /></sentence><sentence text="Transient lower esophageal sphincter relaxations (TLESRs) have been identified as a primary cause of reflux events in patients with gastroesophageal reflux disease (GERD)" /><sentence text=" GABA(B) receptor agonists such as lesogaberan (AZD3355) have been shown to inhibit TLESRs in healthy subjects and patients with GERD, and, therefore, offer a novel therapeutic add-on strategy to acid suppression for the management of GERD"><entity charOffset="35-46" id="DDI-PubMed.21171670.s3.e0" text="lesogaberan" /></sentence><sentence text=" As lesogaberan is being developed as an add-on treatment for the management of patients with GERD who have a partial response to proton pump inhibitor (PPI) therapy, it is important to rule out any clinically important pharmacokinetic drug-drug interaction between lesogaberan and PPIs"><entity charOffset="4-15" id="DDI-PubMed.21171670.s4.e0" text="lesogaberan" /></sentence><sentence text="" /><sentence text="To evaluate the effect of esomeprazole on the pharmacokinetics and safety of lesogaberan and vice versa"><entity charOffset="26-38" id="DDI-PubMed.21171670.s6.e0" text="esomeprazole" /><entity charOffset="77-88" id="DDI-PubMed.21171670.s6.e1" text="lesogaberan" /><pair ddi="false" e1="DDI-PubMed.21171670.s6.e0" e2="DDI-PubMed.21171670.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21171670.s6.e0" e2="DDI-PubMed.21171670.s6.e1" /></sentence><sentence text="" /><sentence text="This was an open-label, randomized, three-way crossover study" /><sentence text=" The study was open to healthy adult male and female subjects" /><sentence text=" The study subjects received treatment with, in random order, lesogaberan (150 mg twice daily [dose interval 12 hours]), esomeprazole (40 mg once daily), and a combination of both, during 7-day treatment periods"><entity charOffset="62-73" id="DDI-PubMed.21171670.s10.e0" text="lesogaberan" /><entity charOffset="121-133" id="DDI-PubMed.21171670.s10.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.21171670.s10.e0" e2="DDI-PubMed.21171670.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21171670.s10.e0" e2="DDI-PubMed.21171670.s10.e1" /></sentence><sentence text="" /><sentence text="The presence or absence of pharmacokinetic interactions between lesogaberan and esomeprazole was assessed by measuring the steady-state area under the plasma concentration-time curves during the dosing interval (AUC(τ)) and the maximum observed plasma concentration (C(max)) for lesogaberan and esomeprazole"><entity charOffset="64-75" id="DDI-PubMed.21171670.s12.e0" text="lesogaberan" /><entity charOffset="80-92" id="DDI-PubMed.21171670.s12.e1" text="esomeprazole" /><entity charOffset="279-290" id="DDI-PubMed.21171670.s12.e2" text="lesogaberan" /><entity charOffset="295-307" id="DDI-PubMed.21171670.s12.e3" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e0" e2="DDI-PubMed.21171670.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e0" e2="DDI-PubMed.21171670.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e0" e2="DDI-PubMed.21171670.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e0" e2="DDI-PubMed.21171670.s12.e3" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e1" e2="DDI-PubMed.21171670.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e1" e2="DDI-PubMed.21171670.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e1" e2="DDI-PubMed.21171670.s12.e3" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e2" e2="DDI-PubMed.21171670.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21171670.s12.e2" e2="DDI-PubMed.21171670.s12.e3" /></sentence><sentence text="" /><sentence text="Thirty male subjects (mean age 23" /><sentence text="2 years, 97% Caucasian) were randomized to treatment and 28 subjects completed the study (one subject was lost to follow-up, and one subject discontinued due to an adverse event)" /><sentence text=" The 95% confidence intervals of the geometric mean ratios for AUC(τ) and C(max) of lesogaberan and esomeprazole administered alone and concomitantly were within the recognized boundaries of bioequivalence (0"><entity charOffset="84-95" id="DDI-PubMed.21171670.s16.e0" text="lesogaberan" /><entity charOffset="100-112" id="DDI-PubMed.21171670.s16.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.21171670.s16.e0" e2="DDI-PubMed.21171670.s16.e0" /><pair ddi="false" e1="DDI-PubMed.21171670.s16.e0" e2="DDI-PubMed.21171670.s16.e1" /></sentence><sentence text="8-1" /><sentence text="25)" /><sentence text=" No new safety concerns were raised during this study" /><sentence text=" The number of patients with adverse events during treatment with lesogaberan alone (n = 17) and concomitantly with esomeprazole (n = 18) were comparable but higher than with esomeprazole alone (n = 10)"><entity charOffset="116-128" id="DDI-PubMed.21171670.s20.e0" text="esomeprazole" /><entity charOffset="175-187" id="DDI-PubMed.21171670.s20.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.21171670.s20.e0" e2="DDI-PubMed.21171670.s20.e0" /><pair ddi="false" e1="DDI-PubMed.21171670.s20.e0" e2="DDI-PubMed.21171670.s20.e1" /></sentence><sentence text=" Paresthesia (episodic, mild, and transient), pharyngitis, and flatulence were the most frequently reported adverse events" /><sentence text="" /><sentence text="There was no observed pharmacokinetic interaction between lesogaberan and esomeprazole when concomitantly administered to healthy subjects, and concomitant therapy was well tolerated"><entity charOffset="74-86" id="DDI-PubMed.21171670.s23.e0" text="esomeprazole" /></sentence><sentence text=" TRIAL REGISTRATION NUMBER (clinicaltrials" /><sentence text="gov): NCT00684190" /><sentence text="" /></document>